ERG (v-ets erythroblastosis virus E26 oncogene like (avian))

Written	2006-08	Liat Rainis-Ganon, Shai Izraeli
		Head, Research section, Pediatric Hemato-Oncology, Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel 52621
Updated	2010-11	Roopika Menon, Martin Braun, Sven Perner
		Institute of Pathology, University Hospital Tuebingen, Liebermeisterstr. 8, D-72076 Tuebingen, Germany

(Note : for Links provided by Atlas : click)

1. Identity

Alias_names	General Information
	v-ets avian erythroblastosis virus E26 oncogene homolog
Alias_symbol (synonym)	erg-3
	p55
Other alias
HGNC (Hugo)	ERG
LocusID (NCBI)	2078
Atlas_Id	53
Location	21q22.2 [Link to chromosome band 21q22]
Location_base_pair	Starts at 38380028 and ends at 38498504 bp from pter ( according to hg19-Feb_2009) [Mapping ERG.png]


	Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.

Fusion genes
(updated 2017)

Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DUX4 (4q35.2) / ERG (21q22.2)	ELF4 (Xq26.1) / ERG (21q22.2)	ELK4 (1q32.1) / ERG (21q22.2)
ERG (21q22.2) / BZW2 (7p21.1)	ERG (21q22.2) / CIDEC (3p25.3)	ERG (21q22.2) / DUX4 (-)
ERG (21q22.2) / DUX4 (4q35.2)	ERG (21q22.2) / DYRK1A (21q22.13)	ERG (21q22.2) / ELF4 (Xq26.1)
ERG (21q22.2) / ERG (21q22.2)	ERG (21q22.2) / EWSR1 (22q12.2)	ERG (21q22.2) / FUS (16p11.2)
ERG (21q22.2) / GMPR (6p22.3)	ERG (21q22.2) / HERPUD1 (16q13)	ERG (21q22.2) / KCNJ6 (21q22.13)
ERG (21q22.2) / NDRG1 (8q24.22)	ERG (21q22.2) / TMPRSS2 (21q22.3)	ERG (21q22.2) / ZNRF3 (22q12.1)
ETS2 (21q22.2) / ERG (21q22.2)	ETV1 (7p21.2) / ERG (21q22.2)	EWSR1 (22q12.2) / ERG (21q22.2)
FUS (16p11.2) / ERG (21q22.2)	HERPUD1 (16q13) / ERG (21q22.2)	HNRNPH1 (5q35.3) / ERG (21q22.2)
NDRG1 (8q24.22) / ERG (21q22.2)	PAK1 (11q13.5) / ERG (21q22.2)	PRKAB2 (1q21.1) / ERG (21q22.2)
SLC45A3 (1q32.1) / ERG (21q22.2)	SMG6 (17p13.3) / ERG (21q22.2)	TMPRSS2 (21q22.3) / ERG (21q22.2)

2. DNA/RNA



	ERG gene locus on the q-arm of chromosome 21 (21q22.2) spanning from 39751949 to 40033704 (according to UCSC genome browser, Feb. 2009 GRCh37/hg19, and Ensemble, Aug. 2010).

Description	The ERG gene belongs to the erythroblast transformation-specific (ETS) family of transcriptions factors. The ERG gene (ETS related gene 1) is located on chromosome 21, and consists of 17 exons, approximately 300 kb DNA in length.
Transcription	The ERG gene forms 20 known transcripts (ranging from 560 to 5034 bp in length), amongst which 15 are coding for proteins, and 5 are non-coding. 8 alternative splice variants are known.
Pseudogene	No observed pseudogenes.

3. Protein

Description	Amongst the 20 known transcripts of the ERG gene, 15 are protein coding. The 15 proteins range from 171 to 486 amino acids in length, and up to 55 kDa in weight.
Expression	On the protein level, ERG is mainly expressed in the nucleus and is rarely seen in the cytoplasm. Basically, in the GNF SymAtlas database, major ERG expression was found to be in CD34+ cells (that include both hematopoietic stem cells and endothelial cells). In detail, ERG is reported to be expressed during early T and B cell development, and down-regulated in later stages of B and T cell differentiation. Also, ERG is expressed in platelets, megakaryoblastic cell lines, primary megakaryoblastic leukemia (AMKL or M7-AML) in Down syndrome patients. Furthermore, ERG is strongly expressed in ERG gene rearranged prostate tissue (both in prostatic cancer tissue and adjacent prostatic intraepithelial neoplasia lesions). Of note, using immunohistochemistry, ERG expression is regularly observed in lymphocytes and small blood vessels.
Localisation	Predominantely nuclear and rarely cytoplasmic.
Function	The ERG protein is a member of the ETS-family and is known to bind to purine-rich sequences. ERG and other members of the same family are downstream regulators of mitogenic signal transduction pathways. They are key regulators of embryonic development, cell proliferation, differentiation, angiogenesis, inflammation, and apoptosis. At the DNA level, isoforms of ERG are known to regulate methylation. Further, ERG is required for platelet adhesion to the subendothelium, inducing vascular cell remodeling. Moreover, hematopoesis, as well as the differentiation and maturation of megakaryocytic cells are regulated by ERG. Overexpression of the ERG protein is suggested to aid in forming solid tumors. However, the exact molecular mechanisms of ERG as a transcription factor are still unknown.
Homology	A member of the ETS transcription factors, most homologous to FLI1.

4. Mutations

Note	No known mutations.

5. Implicated in

Note

Entity	Ewing's sarcoma
Prognosis	The prognostic relevance of an ERG gene fusion or an ERG overexpression in Ewing's sarcoma (EWS-ETS fusion type) is yet to be determined. So far, no prognostic relevance could be shown.
Hybrid/Mutated Gene	If a gene fusion occurs in Ewing's sarcoma, most frequently it is a fusion of EWS to FLI-1 (in app. 85% of cases) or ERG (in app. 10% of cases). Other ETS genes rarely serve as EWS gene fusion partners (in app. 5% of cases).
Abnormal Protein	The EWS gene fuses with the carboxyl terminal of ERG containing the ETS DNA binding domain of ERG. Therefore, the resulting fusion protein deregulates a large number of genes by so far poorly defined mechanisms.
Oncogenesis	In a transgenic mouse model expression of the EWS-ERG in lymphoid progenitors induced T-cell leukemia.


Entity	Acute myeloid leukemia (AML)
Prognosis	Several studies suggest a poorer prognosis for FUS-ERG gene fusion positive AML as compared to non-fused AML. Moreover, an ERG overexpression, not necessarily due to the FUS-ERG gene fusion, predicts an increased relapse risk and shorter survival in AML patients. However, the exact contribution of ERG overexpression to myeloid leukemiogenesis and progression is still unknown.
Hybrid/Mutated Gene	In the FUS-ERG gene fusion, the FUS gene fuses with the carboxyl terminal of ERG containing the ETS DNA binding domain of ERG. Of note, in a single case, a gene fusion of ERG with the myeloid ELF-like factor 1 (ELF4) was detected.
Oncogenesis	The FUS-ERG fusion protein helps in activating the oncogenic activity of transcription factors.


Entity	Prostate cancer
Prognosis	The body of literature is controversial about the prognostic relevance of ERG rearrangements in prostate cancer. Some studies reported an association of the ERG rearrangement with adverse clinical parameters (i.e. time to prostate cancer specific death and the development of hormone-refractory metastasis). On the other hand, some studies demonstrated an association of ERG rearrangement with parameters of more favourable outcome, such as lower Gleason score, stage, volume, better overall survival, or late biochemical recurrence. Interestingly, a subset of studies without any such association was reported as well.
Hybrid/Mutated Gene	In approximately 50% of prostate cancers, the ERG gene is rearranged, i.e. fused to another gene. In case of a rearrangement, TMPRSS2 is the ERG 5' fusion partner in the vast majority of cases (app. 85%). Other known, but rarely occurring ERG fusion partners include NDRG1, SLC45A3, and HERPUD1. The ERG gene rearrangement either occurs due to a deletion, or an insertion.


	Schematic displaying ERG rearrangement status (via FISH) in prostate cancer. The red-labelled centromeric and the green-labelled telomeric probes span the ERG locus on chromosomes 21. If a break-apart occurs, the green signal is either lost (ERG rearrangement through deletion) or translocated (ERG rearrangement through insertion). An ERG break-apart as determined by FISH accounts for a fusion of ERG mainly with TMPRSS2 but also with other 5' fusion partners such as SLC45A3, HERPUD1, or NDRG1. A: Both alleles with wild type (wt) ERG. B: One allele with ERG rearrangement through deletion (single red signal) and the other allele with wt ERG (yellow signal). C: One allele with ERG rearrangement through insertion (separated red and green signal) and the other allele with wt ERG (yellow signal).

Abnormal Protein	An ERG gene rearrangement in prostate cancer mainly results in an androgen dependant ERG overexpression.
Oncogenesis	In-vitro models complement that over expression of truncated ERG and various TMPRSS2-ERG isoforms increase cell migration and invasion. In-vivo recapitulation of ETS fusions by prostate specific expression of truncated ERG in mice resulted in the development of PIN but not carcinoma. Subsequent work on transgenic TMPRSS2-ERG mice develop PIN progressing to invasive cancer, but only in the context of PI3-kinase pathway activation. TMPRSS2-ERG-positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis.


Entity	Acute lymphoblastic leukemia (ALL)
Prognosis	Overexpression of ERG was shown to be a risk factor in adult T-ALL. ALL patients with ERG overexpression were four times more likely to fail long-term recurrence free survival, indicating inferior survival.
Oncogenesis	Studies assessing ERG overexpression in ALL have shown that due to the involvement of ERG in T-cell development, it may have an oncogenic potential.


Entity	Acute megakaryoblastic leukemia (AMKL)
Prognosis	Even though ERG is highly considered to be oncogenic in AMKL, no prognostic relevance has been determined.
Oncogenesis	ERG was found to be expressed megakaryoblastic leukemic cell lines and in primary leukemic cells from DS patients. Moreover, in mouse models, expression of ERG drove megakaryopoiesis and lead to a rapid development of aggressive leukemia.


Entity	Alzheimer's disease (AD)
Note	ERG has been linked to AD, due to an ERG protein overexpression as compared to control patients. This is further supported by experiments conducted on patients suffering from Down syndrome, who gradually develop AD-like symptoms, linked to ERG overexpression.


Entity	Down syndrome (DS)
Note	DS is associated with trisomy of the chromosome 21, where the ERG gene is located. The trisomy is considered to be responsible for an ERG overexpression. In a DS mouse model, an induced functional disomy of the ERG allele corrects some pathologic features of the disease, including myeloproliferation and progenitor cell expansion, suggesting a pathogenic effect of trisomy driven ERG overexpression.


Entity	ERG involvement in endothelial development
Note	ERG has been reported to regulate genes involved in chondrogenesis and angiogenesis and functions as a modulator of endothelial cell differentiation. In an in-vitro study, the decrease of the ERG protein follows a reduction in endothelial cell proliferation and vascular tube formation. In human umbilical vein endothelial cell lines, vascular endothelial growth factor (VEGF) was seen to significantly up-regulate ERG expression. Controversially, on the other hand, ERG expression was shown to inhibit responsiveness to the VEGF receptor in a Down Syndrome mouse model.


Entity	ERG involvement in lymphoid development
Note	ERG was reported to be expressed in during early T and B cell development, and to be down-regulated in later stages of B and T cell differentiation. In detail, the ERG protein modulates the maturation of lymphoid cells. Interestingly, ERG overexpression is associated with T-ALL.

6. Breakpoints

7. Bibliography

At the crossroads: diverse roles of early thymocyte transcriptional regulators.

Anderson MK.

Immunol Rev. 2006 Feb;209:191-211. (REVIEW)

PMID 16448544

High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.

Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK.

J Clin Oncol. 2006 Oct 10;24(29):4714-20. Epub 2006 Sep 5.

PMID 16954520

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD, de la Chapelle A.

Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3915-20. Epub 2004 Mar 8.

PMID 15007164

Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.

Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A, Leyland-Jones B.

Br J Cancer. 2010 Feb 2;102(3):570-6. Epub 2010 Jan 12.

PMID 20068566

Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer.

Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L, Schroder FH, Trapman J, Verhagen PC.

Eur Urol. 2010 May;57(5):830-5. Epub 2009 Aug 22.

PMID 19716227

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. Epub 2009 Apr 26.

PMID 19396168

The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia.

Coskun E, von der Heide EK, Schlee C, Kuhnl A, Gokbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Leuk Res. 2010 Jun 4. [Epub ahead of print]

PMID 20570349

Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.

De Vita S, Canzonetta C, Mulligan C, Delom F, Groet J, Baldo C, Vanes L, Dagna-Bricarelli F, Hoischen A, Veltman J, Fisher EM, Tybulewicz VL, Nizetic D.

Oncogene. 2010 Nov 18;29(46):6102-14. Epub 2010 Aug 9.

PMID 20697343

New human erg isoforms generated by alternative splicing are transcriptional activators.

Duterque-Coquillaud M, Niel C, Plaza S, Stehelin D.

Oncogene. 1993 Jul;8(7):1865-73.

PMID 8510931

BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.

Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W, Mahmoud L.

Int J Lab Hematol. 2010 Apr;32(2):197-205. Epub 2009 Jun 23.

PMID 19555438

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. Epub 2010 Aug 6.

PMID 20693982

EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.

Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA.

J Clin Invest. 1994 Aug;94(2):489-96.

PMID 8040301

Identification of a cell of origin for human prostate cancer.

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON.

Science. 2010 Jul 30;329(5991):568-71.

PMID 20671189

FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.

Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O.

Cancer Res. 2010 Sep 1;70(17):6735-45. Epub 2010 Aug 16.

PMID 20713528

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.

Nat Genet. 2010 Aug;42(8):668-75. Epub 2010 Jul 4.

PMID 20601956

ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status.

Hamalainen M, Juvonen V, Haikio S, Lakkala T, Johansson J, Pelliniemi TT, Salmi TT, Remes K, Kairisto V.

Eur J Haematol. 2010 Oct;85(4):361-2. doi: 10.1111/j.1600-0609.2010.01483.x. Epub 2010 Jul 13.

PMID 20546020

ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB.

Am J Surg Pathol. 2010 Apr;34(4):478-85.

PMID 20220513

Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis.

Heo SH, Choi YJ, Ryoo HM, Cho JY.

J Cell Physiol. 2010 Sep;224(3):734-42.

PMID 20432469

Selective expression of erg isoforms in human endothelial cells.

Hewett PW, Nishi K, Daft EL, Clifford Murray J.

Int J Biochem Cell Biol. 2001 Apr;33(4):347-55.

PMID 11312105

The role of ERG (ets related gene) in cartilage development.

Iwamoto M, Higuchi Y, Enomoto-Iwamoto M, Kurisu K, Koyama E, Yeh H, Rosenbloom J, Pacifici M.

Osteoarthritis Cartilage. 2001;9 Suppl A:S41-7.

PMID 11680687

Complex rearrangement of chromosomes 1, 7, 21, 22 in Ewing sarcoma.

Jinawath N, Morsberger L, Norris-Kirby A, Williams LM, Yonescu R, Argani P, Griffin CA, Murphy KM.

Cancer Genet Cytogenet. 2010 Aug;201(1):42-7.

PMID 20633768

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. Epub 2009 Apr 26.

PMID 19396167

Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript.

Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N, Kaneko Y, Sako M, Kobayashi Y, Tojou A, Miura I, Kakuda H, Funabiki T, Horibe K, Hamaguchi H, Akiyama Y, Bessho F, Yanagisawa M, Hayashi Y.

Blood. 1997 Aug 1;90(3):1192-9.

PMID 9242552

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547.

PMID 20479932

VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2.

Le Bras A, Samson C, Trentini M, Caetano B, Lelievre E, Mattot V, Beermann F, Soncin F.

PLoS One. 2010 Aug 16;5(8):e12156.

PMID 20808444

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslbock M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jurgens H, Kovar H.

J Clin Oncol. 2010 Apr 20;28(12):1982-8. Epub 2010 Mar 22.

PMID 20308673

TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.

Lee K, Chae JY, Kwak C, Ku JH, Moon KC.

Urology. 2010 Nov;76(5):1268.e7-13. Epub 2010 Aug 30.

PMID 20800881

Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.

Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T.

Clin Cancer Res. 2010 May 15;16(10):2845-51. Epub 2010 May 4.

PMID 20442300

The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells.

Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA, Henley KJ, Ellis S, Voss AK, Metcalf D, Hilton DJ, Alexander WS, Kile BT.

Nat Immunol. 2008 Jul;9(7):810-9. Epub 2008 May 25.

PMID 18500345

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, Lafargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2010 Sep 28. [Epub ahead of print]

PMID 20878952

CD99-positive large cell neuroendocrine carcinoma with rearranged EWSR1 gene in an infant: a case of prognostically favorable tumor.

Malone VS, Dobin SM, Jones KA, Donner LR.

Virchows Arch. 2010 Sep;457(3):389-95. Epub 2010 Jul 9.

PMID 20617339

Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ.

Cancer Res. 2010 Jul 1;70(13):5207-12. Epub 2010 Jun 1.

PMID 20516122

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD.

J Clin Oncol. 2005 Dec 20;23(36):9234-42. Epub 2005 Nov 7.

PMID 16275934

Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation.

McLaughlin F, Ludbrook VJ, Cox J, von Carlowitz I, Brown S, Randi AM.

Blood. 2001 Dec 1;98(12):3332-9.

PMID 11719371

ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).

Moore SD, Offor O, Ferry JA, Amrein PC, Morton CC, Dal Cin P.

Leuk Res. 2006 Aug;30(8):1037-42. Epub 2005 Nov 21.

PMID 16303180

Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.

Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L, Kile BT, Alexander WS.

Blood. 2010 May 13;115(19):3966-9. Epub 2009 Dec 9.

PMID 20007548

Two childhood cases of acute leukemia with t(16;21)(p11.2;q22): second case report of infantile acute lymphoblastic leukemia with unusual type of FUS-ERG chimeric transcript.

Oh SH, Park TS, Choi JR, Lee S, Cho SY, Kim SY, Kim J, Park JK, Song SA, Lee JY, Shin JH, Kim HR, Lee JN.

Cancer Genet Cytogenet. 2010 Jul 15;200(2):180-3.

PMID 20620604

Molecular biology of the Ets family of transcription factors.

Oikawa T, Yamada T.

Gene. 2003 Jan 16;303:11-34. (REVIEW)

PMID 12559563

ETS transcription factors: possible targets for cancer therapy.

Oikawa T.

Cancer Sci. 2004 Aug;95(8):626-33. (REVIEW)

PMID 15298723

A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.

Oram SH, Thoms JA, Pridans C, Janes ME, Kinston SJ, Anand S, Landry JR, Lock RB, Jayaraman PS, Huntly BJ, Pimanda JE, Gottgens B.

Oncogene. 2010 Oct 28;29(43):5796-808. Epub 2010 Aug 2.

PMID 20676125

Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16.

Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K, Shimizu N, Kola I, Hertzog PJ.

Gene. 2004 Jan 7;324:65-77.

PMID 14693372

Antibody-based detection of ERG rearrangement-positive prostate cancer.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA.

Neoplasia. 2010 Jul;12(7):590-8.

PMID 20651988

ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA.

Urology. 2010 Apr;75(4):762-7.

PMID 20018353

An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer.

Pfeiffer MJ, Mulders PF, Schalken JA.

Prostate. 2010 Oct 1;70(14):1524-32.

PMID 20687225

The proto-oncogene ERG in megakaryoblastic leukemias.

Rainis L, Toki T, Pimanda JE, Rosenthal E, Machol K, Strehl S, Gottgens B, Ito E, Izraeli S.

Cancer Res. 2005 Sep 1;65(17):7596-602.

PMID 16140924

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.

Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM.

Nature. 2010 Jun 10;465(7299):813-7.

PMID 20535211

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. Epub 2010 Feb 16.

PMID 20160063

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, Lopez-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. Epub 2010 Mar 19.

PMID 20303538

ERG is a megakaryocytic oncogene.

Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, Brady HJ.

Cancer Res. 2009 Jun 1;69(11):4665-73.

PMID 19487285

ERG rearrangement in small cell prostatic and lung cancer.

Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F, Kristiansen G, Perner S.

Histopathology. 2010 Jun;56(7):937-43.

PMID 20636794

Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation.

Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenfuhrer J, Engers R.

BMC Cancer. 2010 Sep 22;10:505.

PMID 20860828

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.

Sci Transl Med. 2010 Mar 31;2(25):25ra23.

PMID 20424012

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. Epub 2010 Jun 24.

PMID 20579941

ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.

Eur Urol. 2009 Aug;56(2):275-86. Epub 2009 Apr 24. (REVIEW)

PMID 19409690

1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Washington MN, Weigel NL.

Endocrinology. 2010 Apr;151(4):1409-17. Epub 2010 Feb 10.

PMID 20147525

Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo.

Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Talukder S, Turunen M, Taipale M, Stunnenberg HG, Ukkonen E, Hughes TR, Bulyk ML, Taipale J.

EMBO J. 2010 Jul 7;29(13):2147-60. Epub 2010 Jun 1.

PMID 20517297

Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators.

Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, Chilarska PM, Kinston S, Ouwehand WH, Dzierzak E, Pimanda JE, de Bruijn MF, Gottgens B.

Cell Stem Cell. 2010 Oct 8;7(4):532-44.

PMID 20887958

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR.

Cancer Cell. 2002 Mar;1(2):133-43.

PMID 12086872

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54.

PMID 20478527

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER.

J Clin Oncol. 2010 Apr 20;28(12):1989-94. Epub 2010 Mar 22.

PMID 20308669

Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression.

van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Revesz T, Staal FJ, van Dongen JJ.

J Immunol. 2005 Nov 1;175(9):5912-22.

PMID 16237084

8. Citation

This paper should be referenced as such :

Menon, R ; Braun, M ; Perner, S

ERG (v-ets erythroblastosis virus E26 oncogene like (avian))

Atlas Genet Cytogenet Oncol Haematol. 2011;15(7):547-553.

Free journal version : [ pdf ] [ DOI ]

On line version : http://atlasgeneticsoncology.usal.es/classic/Genes/ERGID53ch21q22.html

History of this paper:

Izraeli, S ; Rainis-Ganon, L. ERG (v-ets erythroblastosis virus E26 oncogene like (avian)). Atlas Genet Cytogenet Oncol Haematol. 2007;11(1):4-7.

http://documents.irevues.inist.fr/bitstream/handle/2042/38374/08-2006-ERGID53ch21q22.pdf

9. Other Leukemias implicated (Data extracted from papers in the Atlas) [ 9 ]

10. External links

	Nomenclature
HGNC (Hugo)	ERG 3446
	Cards
Atlas	ERGID53ch21q22
Entrez_Gene (NCBI)	ERG 2078 ETS transcription factor ERG
Aliases	erg-3; p55
GeneCards (Weizmann)	ERG
Ensembl hg19 (Hinxton)	ENSG00000157554 [Gene_View]
Ensembl hg38 (Hinxton)	ENSG00000157554 [Gene_View] &nbspENSG00000157554 [Sequence] chr21:38380028-38498504 [Contig_View] ERG [Vega]
ICGC DataPortal	ENSG00000157554
TCGA cBioPortal	ERG
AceView (NCBI)	ERG
Genatlas (Paris)	ERG
WikiGenes	2078
SOURCE (Princeton)	ERG
Genetics Home Reference (NIH)	ERG
	Genomic and cartography
GoldenPath hg38 (UCSC)	ERG - chr21:38380028-38498504 - 21q22.2 [Description] (hg38-Dec_2013)
GoldenPath hg19 (UCSC)	ERG - 21q22.2 [Description] (hg19-Feb_2009)
Ensembl	ERG - 21q22.2 [CytoView hg19] ERG - 21q22.2 [CytoView hg38]
Mapping of homologs : NCBI	ERG [Mapview hg19] ERG [Mapview hg38]
OMIM	165080
	Gene and transcription
Genbank (Entrez)	AA706319 AH001456 AH005535 AH005535 AK297807
RefSeq transcript (Entrez)	NM_001136154 NM_001136155 NM_001243428 NM_001243429 NM_001243432 NM_001243433 NM_001291391 NM_001331025 NM_004449 NM_182918
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)	ERG
Cluster EST : Unigene	Hs.473819 [ NCBI ]
CGAP (NCI)	Hs.473819
Alternative Splicing Gallery	ENSG00000157554
Gene Expression	ERG [ NCBI-GEO ] ERG [ EBI - ARRAY_EXPRESS ] ERG [ SEEK ] ERG [ MEM ]
Gene Expression Viewer (FireBrowse)	ERG [ Firebrowse - Broad ]
SOURCE (Princeton)	Expression in : [Datasets] &nbsp [Normal Tissue Atlas] &nbsp[carcinoma Classsification] &nbsp[NCI60]
Genevestigator	Expression in : [tissues] &nbsp[cell-lines] &nbsp[cancer] &nbsp[perturbations] &nbsp
BioGPS (Tissue expression)	2078
GTEX Portal (Tissue expression)	ERG
Human Protein Atlas	ENSG00000157554-ERG [pathology] [cell] [tissue]
	Protein : pattern, domain, 3D structure
UniProt/SwissProt	P11308 [function] [subcellular_location] [family_and_domains] [pathology_and_biotech] [ptm_processing] [expression] [interaction]
NextProt	P11308 [Sequence] [Exons] [Medical] [Publications]
With graphics : InterPro	P11308
Splice isoforms : SwissVar	P11308
PhosPhoSitePlus	P11308
Domaine pattern : Prosite (Expaxy)	ETS_DOMAIN_1 (PS00345) ETS_DOMAIN_2 (PS00346) ETS_DOMAIN_3 (PS50061) PNT (PS51433)
Domains : Interpro (EBI)	Ets_dom Pointed_dom SAM/pointed_sf WH-like_DNA-bd_sf WH_DNA-bd_sf
Domain families : Pfam (Sanger)	Ets (PF00178) SAM_PNT (PF02198)
Domain families : Pfam (NCBI)	pfam00178 pfam02198
Domain families : Smart (EMBL)	ETS (SM00413) SAM_PNT (SM00251)
Conserved Domain (NCBI)	ERG
DMDM Disease mutations	2078
Blocks (Seattle)	ERG
PDB (RSDB)	1SXE 4IRG 4IRH 4IRI
PDB Europe	1SXE 4IRG 4IRH 4IRI
PDB (PDBSum)	1SXE 4IRG 4IRH 4IRI
PDB (IMB)	1SXE 4IRG 4IRH 4IRI
Structural Biology KnowledgeBase	1SXE 4IRG 4IRH 4IRI
SCOP (Structural Classification of Proteins)	1SXE 4IRG 4IRH 4IRI
CATH (Classification of proteins structures)	1SXE 4IRG 4IRH 4IRI
Superfamily	P11308
Human Protein Atlas [tissue]	ENSG00000157554-ERG [tissue]
Peptide Atlas	P11308
HPRD	01298
IPI	IPI00005012 IPI00220990 IPI00549287 IPI00217544 IPI00788647 IPI00853428 IPI00910082 IPI00853570 IPI00797389 IPI00926377 IPI00974001
	Protein Interaction databases
DIP (DOE-UCLA)	P11308
IntAct (EBI)	P11308
FunCoup	ENSG00000157554
BioGRID	ERG
STRING (EMBL)	ERG
ZODIAC	ERG
	Ontologies - Pathways
QuickGO	P11308
Ontology : AmiGO	RNA polymerase II proximal promoter sequence-specific DNA binding DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription activator activity, RNA polymerase II-specific DNA binding protein binding nucleus cytoplasm regulation of transcription by RNA polymerase II protein phosphorylation signal transduction multicellular organism development cell proliferation cell differentiation positive regulation of transcription by RNA polymerase II positive regulation of transcription by RNA polymerase II ribonucleoprotein complex
Ontology : EGO-EBI	RNA polymerase II proximal promoter sequence-specific DNA binding DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription factor activity, RNA polymerase II-specific DNA-binding transcription activator activity, RNA polymerase II-specific DNA binding protein binding nucleus cytoplasm regulation of transcription by RNA polymerase II protein phosphorylation signal transduction multicellular organism development cell proliferation cell differentiation positive regulation of transcription by RNA polymerase II positive regulation of transcription by RNA polymerase II ribonucleoprotein complex
Pathways : KEGG	Transcriptional misregulation in cancer
NDEx Network	ERG
Atlas of Cancer Signalling Network	ERG
Wikipedia pathways	ERG
	Orthology - Evolution
OrthoDB	2078
GeneTree (enSembl)	ENSG00000157554
Phylogenetic Trees/Animal Genes : TreeFam	ERG
HOGENOM	P11308
Homologs : HomoloGene	ERG
Homology/Alignments : Family Browser (UCSC)	ERG
	Gene fusions - Rearrangements
Fusion : Mitelman	-/21q22.2 [ERG/t(6;21;21)(p21;q22;q22)] &nbsp
Fusion : Mitelman	ELF4/ERG [Xq26.1/21q22.2] &nbsp[t(X;21)(q25;q22)]
Fusion : Mitelman	ERG/GMPR [21q22.2/6p22.3] &nbsp[t(6;21)(p22;q22)]
Fusion : Mitelman	ERG/KCNJ6 [21q22.2/21q22.13] &nbsp[t(21;21)(q22;q22)]
Fusion : Mitelman	ERG/ZNRF3 [21q22.2/22q12.1] &nbsp[t(21;22)(q22;q12)]
Fusion : Mitelman	ETS2/ERG [21q22.2/21q22.2] &nbsp[t(21;21)(q22;q22)]
Fusion : Mitelman	EWSR1/ERG [22q12.2/21q22.2] &nbsp[ins(21;22)(q22;q12q12)] [ins(22;21)(q12;q22q22)]
	[t(11;22)(q24;q12)] [t(21;22)(q22;q12)]
Fusion : Mitelman	FUS/ERG [16p11.2/21q22.2] &nbsp[t(16;21)(p11;q22)] [t(16;21;22)(p11;q22;p11)]

Fusion : Mitelman	HERPUD1/ERG [16q13/21q22.2] &nbsp[t(16;21)(q13;q22)]
Fusion : Mitelman	HNRNPH1/ERG [5q35.3/21q22.2] &nbsp[t(5;21)(q35;q22)]
Fusion : Mitelman	NDRG1/ERG [8q24.22/21q22.2] &nbsp[t(8;21)(q24;q22)]
Fusion : Mitelman	PAK1/ERG [11q13.5/21q22.2] &nbsp[t(11;21)(q14;q22)]
Fusion : Mitelman	SLC45A3/ERG [1q32.1/21q22.2] &nbsp[del(21)(q22q22)] [t(1;21)(q32;q22)]
	[t(21;21)(q22;q22)]
Fusion : Mitelman	TMPRSS2/ERG [21q22.3/21q22.2] &nbsp[del(21)(q22q22)] [t(17;21)(q21;q22)]
	[t(1;21)(q32;q22)] [t(21;21)(q22;q22)] [t(7;21)(p21;q22)]

Fusion : COSMIC	EWSR1 [ERG] - 145 [146] [fusion_149] [fusion_150] [fusion_151] [fusion_152] [fusion_154] [fusion_155] [fusion_156]
	[fusion_159] [fusion_161] [fusion_162]
Fusion : COSMIC	FUS [ERG] - 309 [310] [fusion_311] [fusion_312] [fusion_313] [fusion_314] [fusion_315] [fusion_316] [fusion_318]
	[fusion_319] [fusion_320] [fusion_329] [fusion_624] [fusion_625]
Fusion : COSMIC	NDRG1 [ERG] - 1133 [1134] [fusion_1135] [fusion_1136] [fusion_1146]
Fusion : COSMIC	SLC45A3 [ERG] - 1137 [1138] [fusion_1145]
Fusion : COSMIC	TMPRSS2 [ERG] - 116 [118] [fusion_121] [fusion_123] [fusion_124] [fusion_125] [fusion_126] [fusion_127] [fusion_128]
	[fusion_129] [fusion_130] [fusion_135] [fusion_138] [fusion_139] [fusion_16] [fusion_17] [fusion_18] [fusion_21] [fusion_23]
	[fusion_24] [fusion_25] [fusion_26] [fusion_27] [fusion_28] [fusion_29] [fusion_30] [fusion_36] [fusion_38] [fusion_39]
	[fusion_40] [fusion_41] [fusion_736]
Fusion Portal	ERG 21q22.2 KCNJ6 21q22.13 PRAD
Fusion Portal	ERG 21q22.2 ZNRF3 22q12.1 PRAD
Fusion Portal	HNRNPH1 5q35.3 ERG 21q22.2 LAML
Fusion Portal	NDRG1 8q24.22 ERG 21q22.2 PRAD
Fusion Portal	PAK1 11q13.5 ERG 21q22.2 BRCA
Fusion Portal	TMPRSS2 21q22.3 ERG 21q22.2 PRAD
Fusion : TICdb	EWSR1 [22q12.2] - ERG [21q22.2]
Fusion : TICdb	FUS [16p11.2] - ERG [21q22.2]
Fusion : TICdb	NDRG1 [8q24.22] - ERG [21q22.2]
Fusion : TICdb	TMPRSS2 [21q22.3] - ERG [21q22.2]
Fusion Cancer (Beijing)	TMPRSS2 [21q22.3] - ERG [21q22.2] [FUSC004187] [FUSC004187] [FUSC004187] [FUSC004187] [FUSC004187]
Fusion : Quiver	ERG
	Polymorphisms : SNP and Copy number variants
NCBI Variation Viewer	ERG [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)	ERG
dbVar	ERG
ClinVar	ERG
1000_Genomes	ERG
Exome Variant Server	ERG
ExAC (Exome Aggregation Consortium)	ENSG00000157554
GNOMAD Browser	ENSG00000157554
Varsome Browser	ERG
Genetic variants : HAPMAP	2078
Genomic Variants (DGV)	ERG [DGVbeta]
DECIPHER	ERG [patients] [syndromes] [variants] [genes]
CONAN: Copy Number Analysis	ERG
	Mutations
ICGC Data Portal	ERG
TCGA Data Portal	ERG
Broad Tumor Portal	ERG
OASIS Portal	ERG [ Somatic mutations - Copy number]
Cancer Gene: Census	ERG
Somatic Mutations in Cancer : COSMIC	ERG [overview] [genome browser] [tissue] [distribution]
Mutations and Diseases : HGMD	ERG
LOVD (Leiden Open Variation Database)	Whole genome datasets
LOVD (Leiden Open Variation Database)	LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)	LOVD 3.0 shared installation
BioMuta	search ERG
DgiDB (Drug Gene Interaction Database)	ERG
DoCM (Curated mutations)	ERG (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)	ERG (select a term)
intoGen	ERG
NCG5 (London)	ERG
Cancer3D	ERG(select the gene name)
Impact of mutations	[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
	Diseases
OMIM	165080
Orphanet	3759 22491 22490
DisGeNET	ERG
Medgen	ERG
Genetic Testing Registry	ERG
NextProt	P11308 [Medical]
TSGene	2078
GENETests	ERG
Target Validation	ERG
Huge Navigator	ERG [HugePedia]
snp3D : Map Gene to Disease	2078
BioCentury BCIQ	ERG
ClinGen	ERG
	Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD	2078
Chemical/Pharm GKB Gene	PA27858
Clinical trial	ERG
	Miscellaneous
canSAR (ICR)	ERG (select the gene name)
DataMed Index	ERG
Other database	Cancer Genetics
	Probes
	Litterature
PubMed	387 Pubmed reference(s) in Entrez
GeneRIFs	Gene References Into Functions (Entrez)
CoreMine	ERG
EVEX	ERG
GoPubMed	ERG
iHOP	ERG

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Search in all EBI NCBI

indexed on : Thu Jan 17 18:54:31 CET 2019

For comments and suggestions or contributions, please contact us atlasgeneticsoncology@usal.es.